Department of Pediatrics, Interdisciplinary Laboratory of Medical Investigation, Faculty of Medicine, Federal University of Minas Gerais (UFMG), Belo Horizonte, MG, Brazil.
Curr Drug Saf. 2023;18(3):398-403. doi: 10.2174/1574886317666220518085725.
Losing-salt tubulopathies, such as Bartter syndrome, are rare and usually inherited due to mutations of tubular reabsorption channels of the nephrons. Despite its scarcity, some cases of acquired losing-salt tubulopathies have been described. In this case report, we discuss the main aspects of Bartter syndrome and present a rare pediatric case of probable tacrolimusinduced Bartter-like syndrome in a renal transplanted boy.
A ten-year-old male patient with end-stage renal disease due to endo and extra capillary glomerulonephritis was submitted to renal transplantation from a deceased donor. The post-operatory evolution was satisfactory with normalization of serum creatinine levels, mild hypertension, and the absence of metabolic disorders. The immunosuppression protocol included tacrolimus (0.3 mg/kg/day), mycophenolate (455 mg/m/day) and prednisone (0.5 mg/kg/day). Two months later, the patient was hospitalized due to vomiting, dehydration, intense hypokalemia (1.3 mEq/L), hyponatremia (125 mEq/L), and hypochloremia (84 mmol/L). During hospitalization, he evolved with polydipsia (3000 mL/day) and polyuria (120-160 mL/m2/h) associated with major elevation of urinary potassium excretion, hypercalciuria, mild metabolic alkalosis, hyperfiltration, and proteinuria. The tacrolimus dose was reduced under the suspicion of tubular dysfunction, leading to a better metabolic profile. However, the patient developed a Banff IIb graft rejection, which required pulse therapy and elevation of tacrolimus and mycophenolate doses. Recovery of renal function parameters occurred, but the metabolic disorders worsened following tacrolimus dose elevation. The patient required chronic potassium, chloride, and sodium replacement.
After administering immunosuppressive medications, physicians should be aware of the possibility of Bartter-like or other losing-salt tubulopathies syndromes that can affect metabolic homeostasis. The suspicion must always be considered in the case of a transplanted patient who presents dehydration and hydroelectrolytic disorders right after the commencement of nephrotoxic immunosuppressive drugs, including tacrolimus and cyclosporine.
失盐性肾小管病,如 Bartter 综合征,较为罕见,通常由于肾单位肾小管重吸收通道的突变而遗传。尽管如此,也有一些获得性失盐性肾小管病的病例被描述。在本病例报告中,我们讨论了 Bartter 综合征的主要方面,并介绍了一例罕见的儿科病例,即肾移植后患儿可能由他克莫司诱导的 Bartter 样综合征。
一名十岁男性患者,因内-毛细血管肾小球肾炎导致终末期肾病,接受了来自已故供体的肾移植。术后患者恢复良好,血清肌酐水平正常,存在轻度高血压,但无代谢紊乱。免疫抑制方案包括他克莫司(0.3mg/kg/天)、霉酚酸(455mg/m/天)和泼尼松(0.5mg/kg/天)。两个月后,该患者因呕吐、脱水、严重低钾血症(1.3mEq/L)、低钠血症(125mEq/L)和低氯血症(84mmol/L)住院。住院期间,他出现多饮(3000mL/天)和多尿(120-160mL/m2/h),同时伴有尿钾排泄量显著增加、高钙尿症、轻度代谢性碱中毒、超滤和蛋白尿。怀疑肾小管功能障碍后,他克莫司剂量减少,代谢状况得到改善。然而,患者出现了 IIb 级移植物排斥反应,需要进行脉冲治疗,并增加他克莫司和霉酚酸的剂量。肾功能参数恢复正常,但随着他克莫司剂量的增加,代谢紊乱恶化。患者需要长期补充钾、氯和钠。
在给予免疫抑制药物后,医生应意识到 Bartter 样或其他失盐性肾小管病综合征的可能性,这些疾病可能会影响代谢稳态。在开始使用肾毒性免疫抑制剂(包括他克莫司和环孢素)后,移植患者出现脱水和水电解质紊乱时,应始终考虑这种可能性。